HBsAg level and clinical course in patients with chronic hepatitis B treated with nucleoside analogue: five years of follow-up data
Jeong Han Kim, Yun Jung Choi, Hee Won Moon, Soon Young Ko, Won Hyeok Choe, So Young Kwon
Clin Mol Hepatol. 2013;19(4):409-416.   Published online 2013 Dec 28     DOI: https://doi.org/10.3350/cmh.2013.19.4.409
Citations to this article as recorded by Crossref logo
Clinical Usefulness of HBsAg Quantification in Patients with Chronic Hepatitis B Infection
Ergenekon Karagoz, Alpaslan Tanoglu
Hepatitis Monthly.2017;[Epub]     CrossRef
Hepatitis B s antigen kinetics during treatment with nucleos(t)ides analogues in patients with hepatitis B e antigen-negative chronic hepatitis B
Athanasia Striki, Spilios Manolakopoulos, Melanie Deutsch, Anastasia Kourikou, George Kontos, Hariklia Kranidioti, Emilia Hadziyannis, George Papatheodoridis
Liver International.2017; 37(11): 1642.     CrossRef
Pronounced decline of serum HBsAg in chronic hepatitis B patients with long-term effective nucleos(t)ide analogs therapy
Meng-Lan Wang, En-Qiang Chen, Chuan-Min Tao, Tao-You Zhou, Juan Liao, Dong-Mei Zhang, Juan Wang, Hong Tang
Scandinavian Journal of Gastroenterology.2017; 52(12): 1420.     CrossRef
Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B
Jeong Han Kim, Hee Won Moon, Soon Young Ko, Won Hyeok Choe, So Young Kwon
Clinical and Molecular Hepatology.2014; 20(3): 274.     CrossRef